Ed Miseta - Chief Editor, Clinical Leader & Outsourced Pharma

Ed Miseta

Ed Miseta



Ed Miseta is chief editor for the website Clinical Leader, executive editor for Life Science Leader magazine, conference chair for Clinical Leader Forum, and host of Clinical Leader Live. Ed studied Business Economics at The Pennsylvania State University and also holds a Master’s degree in Business Administration. Ed has been a writer for more than 12 years and has been covering clinical research since January 2013. Ed spent 10 years in banking and investments and also taught economics at Penn State for 8 years. In his current position, Ed interviews clinical executives from pharmaceutical and biotech companies and shares their insights with readers. His primary focus is on best practices, challenges faced and overcome, clinical trends, partnering, and implementing new technologies. He has also moderated numerous speaker panels at industry conferences and trade shows.

ED'S WORK

Success In HIV Treatments Creates Additional Challenges For Drug Developers
Success In HIV Treatments Creates Additional Challenges For Drug Developers HIV drug developers have a whole new set of challenges, including making the regimens simpler better tolerated. In addition, since today’s patients can access these medicines through pharmacies, they no longer have the incentive to take part in clinical studies.  Continue Reading...
Regeneron Manages Clinical Costs In A Fast-Growing Organization
Regeneron Manages Clinical Costs In A Fast-Growing Organization Bari Kowal, VP and head of global clinical operations at Regeneron, says sponsors and CROs must partner to make clinical trial execution more efficient and cost-effective.  Continue Reading...
CRO Leadership Awards Move To Primetime
CRO Leadership Awards Move To Primetime If you are looking for a CRO to help take your molecule through clinical trials and the process of gaining regulatory approval, who do you turn to? It’ not like there is an Angie’s List for CROs.  Continue Reading...
AbbVie Goes All-In On Wearables And Digital Technologies
AbbVie Goes All-In On Wearables And Digital Technologies Three years ago, AbbVie decided to stop talking about using digital technologies in clinical trials and start actually using them. The company then began deploying wearables in three clinical trials.  Continue Reading...
Master Trial Protocols: Better For Pharma, Better For Sites
Master Trial Protocols: Better For Pharma, Better For Sites The primary benefit of master trial protocols for drug companies is the ability to concurrently evaluate multiple studies that may have different objectives, saving both time and money.  Continue Reading...
Navigating The Turbulent Waters From Discovery To Clinical
Navigating The Turbulent Waters From Discovery To Clinical “A partnering deal with a bigger pharma company would certainly help us through [the Phase 3] process,” explains Jeff Davidson, CEO of Keystone Nano, a company that develops nanoparticles that target solid tumors by going after cancer cells and leaving the normal cells intact.  Continue Reading...
Oncology Studies Show Pharma The Future Of Clinical Trials
Oncology Studies Show Pharma The Future Of Clinical Trials What does the future hold for oncology trials, which now comprise around 80 percent of all clinical research? We spoke to three experts who shared their insights into where the industry is headed in 2019 and beyond.  Continue Reading...
A Patient’s Journey To Join A CAR-T Cell Therapy Trial
A Patient’s Journey To Join A CAR-T Cell Therapy Trial Nicole Gularte is currently battling cancer for the 8th time. The last time she had to do so, it seemed a CAR-T cell therapy trial might be the solution. This article is about her long battle with cancer, the struggle to get into a CAR-T cell trial, and the ups and downs she has faced along the way. Her story is an inspiration to others.  Continue Reading...
A Small Biotech Takes On Some Big Clinical Trial Challenges
A Small Biotech Takes On Some Big Clinical Trial Challenges Evofem Biosciences is on the cusp of releasing a revolutionary birth control product. But before the FDA gives its approval, this small biopharma has to navigate two very different clinical trials.  Continue Reading...
Cannabis Trials Move Forward…But Lag In The U.S.
Cannabis Trials Move Forward…But Lag In The U.S. For researchers hoping to conduct clinical trials on cannabis-based products, the U.S. is not the most hospitable place. While other countries are legalizing the drug and conducting research on its possible medicinal uses, state and federal regulations on marijuana in the U.S. continue to stymie its use.  Continue Reading...
More From Ed Miseta